Investor Information

Clinical Spotlight

Pre-Treatment-65yofemale

65-year-old female with Alpha-1 antitrypsin has 28% improvement in FEV₁

Clinical Spotlight:

65-year-old female with Alpha-1 antitrypsin has 28%
improvement in FEV1

Patient Profile
Quality of Life GoalWants to be able to travel with family, go to the beach and play with her grandchild.
Condition
  • Advanced stage COPD/Emphysema; Alpha-1-antitrypsin deficiency
Smoking History
  • 30 pack per year, quit in 1992
Management Medications
  • Perforomist

  • Spiriva

  • Budesonide

  • Albuterol nebulizer

  • HFA

  • Prolastin
Oxygen Use
  • 2-3 LPM NC
Baseline FEV1
  • 24% predicted
Symptoms
  • Severe fatigue

  • Shortness of breath (SOB)

  • Dry cough

  • Unable to participate in family vacations and travel

Procedure Details:

  • Pulmonary rehab prior to treatment 

  • Collateral ventilation negative by Chartis® System

  • Four Zephyr Valves placed in right lower lobe (RLL)

  • Patient had a pneumothorax post-procedure and was discharged to home with a Heimlich valve 

Pre and Post-Imaging:

Pre-procedure

Pre-procedure

Post-procedure

Post-procedure

Pre and Post Lung Function Chart:

ASSESSMENTPRE-PROCEDUREPOST-PROCEDURE
(3 MONTHS)
FEV1660 mL840 mL
FEV1 (% pred)24%31%
RV8.08 L4.91 L
RV (% pred)383%241%
TLC9.87 L7.69 L
TLC (% pred)187%146%
DLCO (% pred)38%50%
6MWD279 m369 m

Case was Completed by:

Franklin Mcguire, MD Frye Regional Medical Center, NC.

Patient Outcome:

  • Reduced oxygen usage from “Continuous” to “As needed”

  • Improved appetite and has gained back weight

  • Energy level improved

  • Anxiety level decreased

  • Confidence improved

  • After the valves were placed, the patient was able to go to the beach with her grandchildren and was able to run around with them

Screen Shot 2022-06-27 at 1.52.58 PM

How the Zephyr Valve Works:

The Zephyr Valve is a one-way valve designed to reduce hyperinflation of the lungs caused by severe emphysema/COPD. In a minimally invasive bronchoscopic procedure, an average of four tiny valves are placed in the airways to block off the diseased parts of the lungs where air gets trapped, causing hyperinflation and severe shortness of breath. The Zephyr Valve reduces lung hyperinflation by allowing trapped air to escape and preventing new air from entering that diseased lobe. This allows the healthier parts of the lung to function better and results in patients being able to breathe more easily and experience less shortness of breath.¹ 

The Zephyr Endobronchial Valve is removable, and thus preserves future therapy options. 

If you have a patient to refer, find a treatment center in your area.

Find a Center

Zephyr Valve Patient Benefits and Risks:

Patients treated report significant improvements in lung function, exercise tolerance, and quality of life.1

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

Results from clinical spotlights are not necessarily predictive of results in other cases. Results in other cases may vary.

GLO-EN-1483-v1  
Mahajan-Clinical

74-year-old male with modest improvement in PFTs, able to walk more and sleep better

Clinical Spotlight:

74-year-old male with modest improvement in PFTs, able to walk more and sleep better

Patient Profile
Quality of Life GoalBe able to walk a golf course with multiple stops, take trash to the end of steep driveway without difficulty, sleep better
Condition
  • Advanced stage Emphysema/COPD (diagnosed at age 58)
Smoking History
  • Yes, but quit with Dr. Sukkar's help
Management Medications
  • Breo


  • Singulair


  • ProAir


  • Spiriva


  • Revatio


  • Uroxatral

  • Lipitor


  • Zithromax


  • Fasenra


  • Hydrodiuril


  • Jardiance


  • Glucophage
Oxygen Use
  • None
Baseline FEV1
  • 48% (1390 mL)
Symptoms
  • Chronic bronchitis

  • Shortness of breath with little exertion

  • Mobility issues

Procedure Details:

  •  Had pulmonary rehab prior to treatment 

  • StratX® report showed 100% complete fissure on the left side and 56% destruction in the target lobe (Left Lower Lobe) 

  • Collateral ventilation negative by Chartis® Pulmonary Assessment System 

  • Five Zephyr Valves placed in left lower lobe (LLL) 

  • Three-night hospitalization prior to discharge 

Pre and Post-Imaging:

Pre-procedure

Pre-procedure

Post-procedure

Post-procedure

Patient Profile
Quality of Life GoalBe able to walk a golf course with multiple stops, take trash to the end of steep driveway without difficulty, sleep better
Condition
  • Advanced stage Emphysema/COPD (diagnosed at age 58)
Smoking History
  • Yes, but quit with Dr. Sukkar's help
Management Medications
  • Breo


  • Singulair


  • ProAir


  • Spiriva


  • Revatio


  • Uroxatral

  • Lipitor


  • Zithromax


  • Fasenra


  • Hydrodiuril


  • Jardiance


  • Glucophage
Oxygen Use
  • None
Baseline FEV1
  • 48% (1390 mL)
Symptoms
  • Chronic bronchitis

  • Shortness of breath with little exertion

  • Mobility issues

Procedure Details:

  •  Had pulmonary rehab prior to treatment 

  • StratX® report showed 100% complete fissure on the left side and 56% destruction in the target lobe (Left Lower Lobe) 

  • Collateral ventilation negative by Chartis® Pulmonary Assessment System 

  • Five Zephyr Valves placed in left lower lobe (LLL) 

  • Three-night hospitalization prior to discharge 

Pre and Post-Imaging:

Pre-procedure

Pre-procedure

Post-procedure

Post-procedure

Pre and Post Lung Function Chart:

ASSESSMENTPRE-PROCEDUREPOST-PROCEDURE
(3 MONTHS)
FEV11390 mL1460 mL
FEV1 (% pred)48%52%
RV4530 mL4080 mL
RV (% pred)172%156%
TLC124%108%
6MWD527 m554 m

Case was Completed by:

Dr. Amit “Bobby” Mahajan at Inova Fairfax Hospital, Fairfax, VA

Patient was Referred by:

Dr. Adlah Sukkar, MD, Pulmonologist

Patient Outcome:

  • No oxygen use changes 

  • No hospitalizations since treatment 

  • Walking three to five miles a day now and can walk 23-minute mile 

  • Sleeping better 

Case-Study-Mahajan-74-male-results

Pre and Post Lung Function Chart:

ASSESSMENTPRE-PROCEDUREPOST-PROCEDURE
(3 MONTHS)
FEV11390 mL1460 mL
FEV1 (% pred)48%52%
RV4530 mL4080 mL
RV (% pred)172%156%
TLC124%108%
6MWD527 m554 m

Case was Completed by:

Dr. Amit “Bobby” Mahajan at Inova Fairfax Hospital, Fairfax, VA

Patient was Referred by:

Dr. Adlah Sukkar, MD, Pulmonologist

Patient Outcome:

  • No oxygen use changes 

  • No hospitalizations since treatment 

  • Walking three to five miles a day now and can walk 23-minute mile 

  • Sleeping better 

Case-Study-Mahajan-74-male-results

How the Zephyr Valve Works:

The Zephyr Valve is a one-way valve designed to reduce hyperinflation of the lungs caused by severe emphysema/COPD. In a minimally invasive bronchoscopic procedure, an average of four tiny valves are placed in the airways to block off the diseased parts of the lungs where air gets trapped, causing hyperinflation and severe shortness of breath. The Zephyr Valve reduces lung hyperinflation by allowing trapped air to escape and preventing new air from entering that diseased lobe. This allows the healthier parts of the lung to function better and results in patients being able to breathe more easily and experience less shortness of breath.¹ 

The Zephyr Endobronchial Valve is removable, and thus preserves future therapy options. 

If you have a patient to refer, find a treatment center in your area.

Find a Center

Zephyr Valve Patient Benefits and Risks:

Patients treated report significant improvements in lung function, exercise tolerance, and quality of life.1

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

Results from clinical spotlights are not necessarily predictive of results in other cases. Results in other cases may vary.

GLO-EN-754-v3  
Kurman-Featured

65-year-old male with FEV₁ improvement from 24% to 31% with Zephyr Valves

Clinical Spotlight

65-year-old male with FEV₁ improvement from
24% to 31% with Zephyr Valves

Patient Profile
Quality of Life GoalBe able to breathe without struggling and move around without difficulty
Condition
  • Diffuse homogeneous emphysema
Smoking History
  • 30 pack-years
Management Medications
  • Maximal medical therapy with a
    LAMA, LABA, ICS, prednisone 5mg
    daily, and roflumilast
Oxygen Use
  • 3L/min
Baseline FEV1
  • 24% predicted
Symptoms
  • Shortness of breath (SOB)

  • Incapacitating dyspnea
Special Notes
  • Comorbidities: Chronic hypoxia, lupus, rheumatoid arthritis, diastolic heart failure, and pulmonary hypertension (TTE: PASP 59 mm Hg., RHC:PAP 35/21/26)

Procedure Details:

  • Collateral ventilation negative (confirmed with Chartis® Pulmonary Assessment System) 

  • Six Zephyr® Valves placed in left upper lobe (LUL) 

  • Total procedure time—25 mins 

Pre and Post Imaging:

Pre-procedure

Pre-procedure

Evidence of hyperinflation with flattening of the diaphragm

Post-procedure

Post-procedure

Atelectasis of LUL with elevation of left hemidiaphragm

Pre and Post Lung Function Chart:

ASSESSMENTPRE-PROCEDUREPOST-PROCEDURE
(3 MONTHS)
FEV1 (% pred)24%31%
RV (% pred)235%129%
TLC (% pred)126%95%
DLCO (% pred)46%53%
6MWD160 m320 m
Oxygen Use3L/min2L/min

Case was Completed by:

Dr. Jonathan Kurman at Medical College of Wisconsin, Wauwatosa, WI 

Patient Outcome:

  • 33% decrease in oxygen use 

  • 100% increase in 6MWD 

  • 30% increase in FEV1 

  • Post-treatment StratX® Lung Report shows 100% Target lobar volume reduction (TLVR) with 1532 mL inspiratory volume 

  • Disease symptoms are more controlled 

  • Overall improvement in quality of life 

  • Able to handle everyday tasks around the house 

COPD-treatment-results-65

How the Zephyr Valve Works:

The Zephyr Valve is a one-way valve designed to reduce hyperinflation of the lungs caused by severe emphysema/COPD. In a minimally invasive bronchoscopic procedure, an average of four tiny valves are placed in the airways to block off the diseased parts of the lungs where air gets trapped, causing hyperinflation and severe shortness of breath. The Zephyr Valve reduces lung hyperinflation by allowing trapped air to escape and preventing new air from entering that diseased lobe. This allows the healthier parts of the lung to function better and results in patients being able to breathe more easily and experience less shortness of breath.1

The Zephyr Endobronchial Valve is removable, and thus preserves future therapy options.

If you have a patient to refer, find a treatment center in your area.

Find a Center

Zephyr Valve Patient Benefits and Risks:

Patients treated report significant improvements in lung function, exercise tolerance, and quality of life.1

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

Results in other cases may vary.

GLO-EN-1318-v1

Important Safety Information: The Pulmonx Zephyr Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events. Caution: Federal law restricts this device to sale by or on the order of a physician.

73yoMale-01

73-year-old male with severe dyspnea treated with Zephyr Valves

Clinical Spotlight

73-year-old male with severe dyspnea treated with Zephyr Valves

Patient Profile
Quality of Life GoalBeing able to walk without difficulty, work in woodworking shop, do yardwork, help brother put up fence posts
Condition
  • COPD, chronic AFib, HTN, iron deficiency
Smoking History
  • None
Management Medications
  • Albuterol

  • Breo

  • Incruse

  • Lipitor

  • Zithromax

  • Bumex

  • Klonopin

  • Jantoven

  • Metoprolol

  • Pantoprazole

  • Prednisone

  • Cialis
Oxygen Use
  • 3–4 LPM NC
Baseline FEV1
  • 23% predicted (730 mL)
Symptoms
  • Multiple episodes of bronchitis

  • Collapsed lung

  • Perception of extreme difficulty breathing in and out

Procedure Details:

  • Had pulmonary rehab prior to treatment
  • StratX® shows 100% fissure on the left and 61% emphysema destruction in the target lobe (left lower lobe-LLL); LLL inspiratory volume of 1982 mL
  • Collateral ventilation negative
  • Four Zephyr® Valves placed in LLL
  • Three-night hospitalization, no pneumothorax or exacerbation

Pre and Post Imaging:

Pre-procedure

Pre-procedure

Post-procedure

Post-procedure

Pre and Post Lung Function Chart:

ASSESSMENTPRE-PROCEDUREPOST-PROCEDURE
(3 MONTHS)
FEV1730 mL850 mL
FEV1 (% pred)23%27%
RV4510 mL3470 mL
RV (% pred)175%130%
TLC (% pred)110%86%
6MWD221 m262 m

Case was Completed by:

Dr. Amit “Bobby” Mahajan at Inova Fairfax Hospital, Fairfax, VA

Patient Outcome:

  • Not as short of breath 

  • Restarted pulmonary rehab and expected to see further improvements in breathing

  • Oxygen use has been reduced to 2 LPM NC 

  • Able to get up and walk around without feeling extreme shortness of breath

Zephyr-Valve-treatment-results-73

How the Zephyr Valve Works:

The Zephyr Valve is a one-way valve designed to reduce hyperinflation of the lungs caused by severe emphysema/COPD. In a minimally invasive bronchoscopic procedure, an average of four tiny valves are placed in the airways to block off the diseased parts of the lungs where air gets trapped, causing hyperinflation and severe shortness of breath. The Zephyr Valve reduces lung hyperinflation by allowing trapped air to escape and preventing new air from entering that diseased lobe. This allows the healthier parts of the lung to function better and results in patients being able to breathe more easily and experience less shortness of breath.1

The Zephyr Endobronchial Valve is removable, and thus preserves future therapy options.

If you have a patient to refer, find a treatment center in your area.

Find a Center

Zephyr Valve Patient Benefits and Risks:

Patients treated report significant improvements in lung function, exercise tolerance, and quality of life.1

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

Results from clinical spotlights are not necessarily predictive of results in other cases. Results in other cases may vary.

GLO-EN-735-v4

Important Safety Information: The Pulmonx Zephyr Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events. Caution: Federal law restricts this device to sale by or on the order of a physician.

Seides-62-year-old-female-Marked-Lung-Volume-Reduction

62-year-old female with marked reduction in volume in the treated lung

Clinical Spotlight

62-year-old female with marked reduction in volume in the treated lung

Patient Profile
Quality of Life GoalWants to be more active, keep up with kids and grandkids
Condition
  • Diagnosed with COPD/emphysema
    12 years ago
Smoking History
  • 40 packs/day (quit in 2015)
Management Medications
  • Stiolto Respimat

  • Flovent

  • Xopenex
Oxygen Use
  • None
Baseline FEV1
  • 32% predicted
Symptoms
  • Shortness of breath

  • Dyspnea on exertion

  • Difficult activities of daily living

  • Difficulty walking
Special Notes
  • Increase in symptoms despite maximum medical therapy in years leading up to Zephyr Valve treatment

Procedure Details:

  •  Pulmonary rehab prior to treatment 

  • Collateral ventilation negative (confirmed with Chartis®) System 

  • Four Zephyr® Valves placed in left upper lobe (LUL) 

  • Patient tolerated the procedure well, no adverse events 

  • Three-night hospital stay for monitoring 

Pre and Post-Procedure Imaging:

Pre-procedure

Pre-procedure

Post-procedure

Post-procedure

Pre and Post-Procedure Lung Function Chart:

ASSESSMENTPRE-PROCEDUREPOST-PROCEDURE
(3 MONTHS)
FEV10.68 mL1.04 mL
FEV1 (% pred)32%49%
RV584 mL358 mL
RV (% pred)386%237%
TLC786 mL568 mL
TLC (% pred)195%141%
DLCO (% pred)40%45%
6MWD335 m457 m

Case was Completed by:

Dr. Benjamin Seides at Central DuPage Hospital, Winfield, IL 

Patient was Referred by:

Dr. Linda M. Lam (Pulmonary, Critical Care) 

Patient Outcome:

 Patient had excellent response with: 

  • Marked improvement in exertional capacity, including long walks 

  • No hospitalizations since treatment 

  • Breathing is easier, less shortness of breath 

  • Remains on daily maintenance medications 

  • Overall improvement in quality of life 

Seides-62-year-old-female-Marked-Lung-Volume-Reduction
Marked-Reduction-Lung-Volume-COPD

How the Zephyr Valve Works:

The Zephyr Valve is a one-way valve designed to reduce hyperinflation of the lungs caused by severe emphysema/COPD. In a minimally invasive bronchoscopic procedure, an average of four tiny valves are placed in the airways to block off the diseased parts of the lungs where air gets trapped, causing hyperinflation and severe shortness of breath. The Zephyr Valve reduces lung hyperinflation by allowing trapped air to escape and preventing new air from entering that diseased lobe. This allows the healthier parts of the lung to function better and results in patients being able to breathe more easily and experience less shortness of breath.1

The Zephyr Endobronchial Valve is removable, and thus preserves future therapy options.

If you have a patient to refer, find a treatment center in your area.

Find a Center

Zephyr Valve Patient Benefits and Risks:

Patients treated report significant improvements in lung function, exercise tolerance, and quality of life.1

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

Results from clinical spotlights are not necessarily predictive of results in other cases. Results in other cases may vary.

GLO-EN-674-v2

Important Safety Information: The Pulmonx Zephyr Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events. Caution: Federal law restricts this device to sale by or on the order of a physician.